Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This investigational study involves treatment with an Ad/PSA vaccine for men with prostate cancer who present with evidence of hormone refractory metastatic disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21

NCT00583752

Recurrent Prostate Cancer

COMPLETED PHASE2

A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate

NCT00001382

Prostatic Neoplasms

COMPLETED PHASE1

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

NCT00831467

Hormonal Refractory Prostate Cancer

COMPLETED PHASE1/PHASE2

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005947

Prostate Cancer

COMPLETED PHASE3

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005992

Prostate Cancer

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects in this trial will be eligible if they have recent evidence of hormone refractory disease (D3) and either (a) have a positive bone scan or a positive CT scan (with obvious soft tissue metastasis or lymph nodes \>1 cm), with a PSA doubling time of \>/= 12 months, a total PSA of \< 5 mg/ml, and are asymptomatic; or (b) have a negative bone scan with any PSA doubling time, are asymptomatic, and are not a candidate for chemotherapy.

This is a virus vaccine in which the gene for prostate specific antigen (PSA) has been placed into a common cold virus termed adenovirus (Ad) to produce this Ad/PSA product. The purpose of this study is to determine whether vaccination with the Ad/PSA vaccine will induce an anti-PSA immunity that will result in the destruction of the remaining prostate cancer cells.

Subjects will be vaccinated three times, each injection administered at 30-day intervals. Based upon our earlier clinical trial, the vaccine is considered safe and should not induce any major side effects. The investigators hope that vaccination with this PSA virus will cause the body to produce immunity to the PSA and that immunity will destroy any cell that produces PSA. Since the only cells left in the body that produce PSA will be the cancer cells, the investigators propose that the vaccination and ensuing anti-PSA immunity will kill the prostate cancer cells. Importantly, this treatment should not cause any major side effects as would treatment with anti-cancer drugs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hormone Refractory Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adenovirus/PSA Vaccine

Participants will receive three injections of 0.16 ml. (0.125 ml. vaccine + 0.035 ml. Gelfoam) of the Ad/PSA subcutaneously

Group Type EXPERIMENTAL

ADENOVIRUS/PSA VACCINE

Intervention Type BIOLOGICAL

1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ADENOVIRUS/PSA VACCINE

1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men with prostate cancer who present with evidence of hormone refractory disease (D3).
* Men with a positive bone scan or a positive CT scan (with obvious soft tissue metastasis or lymph nodes \>1 cm), a PSA doubling time of \>/= 6 months, and a total PSA of \<10 ng/ml, and asymptomatic OR men with a negative bone scan and a negative CT scan with any PSA doubling time and asymptomatic.
* Scans must be obtained within 6 weeks of initiation of treatment.
* Written informed consent.
* Age \>/= 18 years.
* Required laboratory values (obtained within 2 weeks of initiation of treatment)
* Serum creatinine \</= 2.0 mg/dL
* Adequate hematologic function: granulocytes \>/= 1800 per mm3, platelets \>/= 100,000 per mm3, WBC \>/= 3700, and lymphocytes \>590.
* Adequate hepatocellular function: AST \<3x upper limit of normal and total bilirubin \<1.5 mg/dl (unless bilirubin elevation is consistent with Gilbert's syndrome).
* Castrate levels of testosterone of \</= 50 ng/ml.
* PSA can be used as an eligibility criterion must be drawn within 28 days prior to injection number 1 and will be drawn on Day 1 for use as a baseline value.

Exclusion Criteria

* Active or unresolved clinically significant infection.
* Parenteral antibiotics \<7 days prior to initiation of treatment.
* Evidence of prior or current CNS metastases. Specific imaging is not necessary in the absence of signs or symptoms.
* Co-morbid medical conditions which would result in a life expectancy (participation) of less than 1 year.
* Patients with compromised immune systems; congenital, acquired, or drug-induced (immunosuppressive agents) will be excluded from the study. Use of prednisone at doses higher than 10 mg daily (or equipotent steroid doses) for more than 7 days within 3 months of initiation of treatment is not allowed.
* Pre-existing malignancies that required treatment within the past 5 years except for basal or squamous cell cancers of the skin.
* Prior participation in any vaccine studies for non-infectious diseases.
* Prior chemotherapy, defined as prior cytotoxic chemotherapy for prostate cancer (or any cancer unless more than 5 years have elapsed). Examples of cytotoxic chemotherapy are mitoxantrone/prednisone and taxanes. Drugs such as Casodex or ketoconazole treatment must have been completed at least 6 weeks prior to initiation of treatment.
* The inability to understand the language and the clinical protocol.
* Allergy or religious objection to pork products; Gelfoam is produced from pork.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No